{"sequenceId":"845366568947","id":"34207245525","language":"English","title":"Somewhat Critical News Coverage Somewhat Unlikely to Impact Zynerba Pharmaceuticals (ZYNE) Stock Price","content":"News stories about Zynerba Pharmaceuticals (NASDAQ:ZYNE) have trended somewhat negative this week, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Zynerba Pharmaceuticals earned a daily sentiment score of -0.03 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 47.8333130843725 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.    These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:        Zynerba Pharmaceuticals Inc (ZYNE) Expected to Announce Earnings of -$0.74 Per Share (americanbankingnews.com)  Insider Buying: Zynerba Pharmaceuticals Inc (ZYNE) Major Shareholder Purchases 5,885 Shares of Stock (americanbankingnews.com)  Zynerba Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference (finance.yahoo.com)  Return on Equity (ROE) in the Limelight Overstock.com, Inc. (NASDAQ:OSTK), Essent Group Ltd. (NYSE:ESNT … (stocksnewspoint.com)  Stock on the Brink of a Move? Zynerba Pharmaceuticals, Inc. (NasdaqGM:ZYNE) Price Index Reaches 0.74437 (derbynewsjournal.com)   ZYNE has been the topic of a number of research reports. Cantor Fitzgerald initiated coverage on Zynerba Pharmaceuticals in a research note on Monday, March 5th. They issued a “buy” rating and a $17.00 price objective on the stock. HC Wainwright  set a $23.00 price objective on Zynerba Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, March 6th. Oppenheimer  reissued a “hold” rating on shares of Zynerba Pharmaceuticals in a research note on Tuesday, March 13th. Seaport Global Securities  reissued a “buy” rating on shares of Zynerba Pharmaceuticals in a research note on Tuesday, March 13th. Finally, Zacks Investment Research raised Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a research report on Thursday, March 15th. One investment analyst  has rated the stock with a sell rating, five have issued  a hold rating and eight have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $17.86.    Shares of Zynerba Pharmaceuticals traded up $0.25, reaching $10.92, on Friday, Marketbeat Ratings reports. 298,834 shares of the company were exchanged, compared to its average volume of 294,790. The firm has a market capitalization of $138.19 million, a PE ratio of -4.40 and a beta of 4.87. Zynerba Pharmaceuticals has a fifty-two week low of $5.42 and a fifty-two week high of $20.73.  Zynerba Pharmaceuticals (NASDAQ:ZYNE) last announced its earnings results on Tuesday, May 8th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.23).  equities analysts anticipate that  Zynerba Pharmaceuticals will post -3.03 earnings per share for the current fiscal year.    In related news, major shareholder Michael Rapp bought 10,000 shares of the business’s stock in a transaction dated Thursday, March 22nd. The shares were bought at an average cost of $9.28 per share, with a total value of $92,800.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website . Insiders have bought 30,885 shares of company stock worth $311,198 over the last ninety days. 12.67% of the stock is owned by insiders.    Zynerba Pharmaceuticals Company Profile    Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome.","contentWithMarkup":"News stories about Zynerba Pharmaceuticals (NASDAQ:ZYNE) have trended somewhat negative this week, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Zynerba Pharmaceuticals earned a daily sentiment score of -0.03 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 47.8333130843725 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.    These are some of the news headlines that may have effected Accern Sentiment Analysis’s scoring:        Zynerba Pharmaceuticals Inc (ZYNE) Expected to Announce Earnings of -$0.74 Per Share (americanbankingnews.com)  Insider Buying: Zynerba Pharmaceuticals Inc (ZYNE) Major Shareholder Purchases 5,885 Shares of Stock (americanbankingnews.com)  Zynerba Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference (finance.yahoo.com)  Return on Equity (ROE) in the Limelight Overstock.com, Inc. (NASDAQ:OSTK), Essent Group Ltd. (NYSE:ESNT … (stocksnewspoint.com)  Stock on the Brink of a Move? Zynerba Pharmaceuticals, Inc. (NasdaqGM:ZYNE) Price Index Reaches 0.74437 (derbynewsjournal.com)   ZYNE has been the topic of a number of research reports. Cantor Fitzgerald initiated coverage on Zynerba Pharmaceuticals in a research note on Monday, March 5th. They issued a “buy” rating and a $17.00 price objective on the stock. HC Wainwright  set a $23.00 price objective on Zynerba Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, March 6th. Oppenheimer  reissued a “hold” rating on shares of Zynerba Pharmaceuticals in a research note on Tuesday, March 13th. Seaport Global Securities  reissued a “buy” rating on shares of Zynerba Pharmaceuticals in a research note on Tuesday, March 13th. Finally, Zacks Investment Research raised Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a research report on Thursday, March 15th. One investment analyst  has rated the stock with a sell rating, five have issued  a hold rating and eight have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $17.86.    Shares of Zynerba Pharmaceuticals traded up $0.25, reaching $10.92, on Friday, Marketbeat Ratings reports. 298,834 shares of the company were exchanged, compared to its average volume of 294,790. The firm has a market capitalization of $138.19 million, a PE ratio of -4.40 and a beta of 4.87. Zynerba Pharmaceuticals has a fifty-two week low of $5.42 and a fifty-two week high of $20.73.  Zynerba Pharmaceuticals (NASDAQ:ZYNE) last announced its earnings results on Tuesday, May 8th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.23).  equities analysts anticipate that  Zynerba Pharmaceuticals will post -3.03 earnings per share for the current fiscal year.    In related news, major shareholder Michael Rapp bought 10,000 shares of the business’s stock in a transaction dated Thursday, March 22nd. The shares were bought at an average cost of $9.28 per share, with a total value of $92,800.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website . Insiders have bought 30,885 shares of company stock worth $311,198 over the last ninety days. 12.67% of the stock is owned by insiders.    Zynerba Pharmaceuticals Company Profile    Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome.","tags":[],"publishedDate":"2018-06-02T21:54:52Z","harvestDate":"2018-06-02T21:57:19Z","estimatedPublishedDate":"2018-06-02T21:54:52Z","url":"http://ct.moreover.com/?a=34207245525&p=1u0&v=1&x=A24XxZtFFLRn5elXsqO7nw","originalUrl":"https://www.com-unik.info/2018/06/02/somewhat-critical-news-coverage-somewhat-unlikely-to-impact-zynerba-pharmaceuticals-zyne-stock-price.html","outboundUrls":["https://www.americanbankingnews.com/?p=6901829","https://www.americanbankingnews.com/?p=6899415","https://finance.yahoo.com/news/zynerba-pharmaceuticals-present-jefferies-2018-120000187.html?.tsrc=rss","http://www.stocksnewspoint.com/index.php/2018/05/30/return-on-equity-roe-in-the-limelight-overstock-com-inc-nasdaqostk-essent-group-ltd-nyseesnt-zynerba-pharmaceuticals-inc-nasdaqzyne/","https://www.derbynewsjournal.com/2018/05/30/stock-on-the-brink-of-a-move-zynerba-pharmaceuticals-inc-nasdaqgmzyne-price-index-reaches-0-74437/","http://www.americanconsumernews.net/scripts/click.aspx?Zacks=1","https://www.marketbeat.com/","http://www.sec.gov/Archives/edgar/data/1405685/000161577418002065/xslF345X03/s109443_form4.xml"],"wordCount":"612","dataFormat":"text","duplicateGroupId":"34207245525","media":{"audio":[],"images":[],"video":[],"logo":[]},"publishingPlatform":{},"adultLanguage":"false","topics":[{"name":"Pharma industry news","group":"Industry"},{"name":"Finance latest","group":"Finance"}],"companies":[{"name":"Zynerba Pharmaceuticals Inc","symbol":"ZYNE","exchange":"NAS","isin":"US98986X1090","titleCount":1,"contentCount":17,"primary":true},{"name":"Zynerba Pharmaceuticals Inc","symbol":"6ZY","exchange":"MUN","isin":"US98986X1090","titleCount":1,"contentCount":17,"primary":true},{"name":"Zynerba Pharmaceuticals Inc","symbol":"6ZY","exchange":"STU","isin":"US98986X1090","titleCount":1,"contentCount":17,"primary":true},{"name":"Zynerba Pharmaceuticals Inc","symbol":"6ZY","exchange":"FRA","isin":"US98986X1090","titleCount":1,"contentCount":17,"primary":true},{"name":"Altaba Inc","symbol":"AABA","exchange":"MEX","isin":"US0213461017","titleCount":0,"contentCount":1,"primary":false},{"name":"Altaba Inc","symbol":"AABA","exchange":"BUE","isin":"ARDEUT111051","titleCount":0,"contentCount":1,"primary":false},{"name":"Altaba Inc","symbol":"AABA","exchange":"NAS","isin":"US0213461017","titleCount":0,"contentCount":1,"primary":false},{"name":"Altaba Inc","symbol":"ALA","exchange":"BER","isin":"US0213461017","titleCount":0,"contentCount":1,"primary":false},{"name":"Altaba Inc","symbol":"ALA","exchange":"MUN","isin":"US0213461017","titleCount":0,"contentCount":1,"primary":false},{"name":"Altaba Inc","symbol":"ALA","exchange":"ETR","isin":"US0213461017","titleCount":0,"contentCount":1,"primary":false},{"name":"Altaba Inc","symbol":"ALA","exchange":"HAN","isin":"US0213461017","titleCount":0,"contentCount":1,"primary":false},{"name":"Altaba Inc","symbol":"AABA","exchange":"SWX","isin":"US0213461017","titleCount":0,"contentCount":1,"primary":false},{"name":"Altaba Inc","symbol":"ALA","exchange":"DUS","isin":"US0213461017","titleCount":0,"contentCount":1,"primary":false},{"name":"Altaba Inc","symbol":"ALA","exchange":"STU","isin":"US0213461017","titleCount":0,"contentCount":1,"primary":false},{"name":"Altaba Inc","symbol":"ALA","exchange":"HAM","isin":"US0213461017","titleCount":0,"contentCount":1,"primary":false},{"name":"Altaba Inc","symbol":"ALA","exchange":"FRA","isin":"US0213461017","titleCount":0,"contentCount":1,"primary":false},{"name":"Altaba Inc","symbol":"AABA","exchange":"LIM","isin":"US0213461017","titleCount":0,"contentCount":1,"primary":false},{"name":"Altaba Inc","symbol":"AABA","exchange":"SGO","isin":"US0213461017","titleCount":0,"contentCount":1,"primary":false},{"name":"Altaba Inc","symbol":"ATBA","exchange":"WBO","isin":"US0213461017","titleCount":0,"contentCount":1,"primary":false},{"name":"Altaba Inc","symbol":"AABA","exchange":"MIL","isin":"US0213461017","titleCount":0,"contentCount":1,"primary":false},{"name":"Essent Group Ltd","symbol":"EG0","exchange":"FRA","isin":"BMG3198U1027","titleCount":0,"contentCount":1,"primary":false},{"name":"Essent Group Ltd","symbol":"EG0","exchange":"BER","isin":"BMG3198U1027","titleCount":0,"contentCount":1,"primary":false},{"name":"Essent Group Ltd","symbol":"ESNT","exchange":"NYS","isin":"BMG3198U1027","titleCount":0,"contentCount":1,"primary":false},{"name":"Global Securities Ltd","symbol":"530657","exchange":"BOM","isin":"INE742K01018","titleCount":0,"contentCount":1,"primary":false},{"name":"Healthcare Co Ltd","symbol":"603313","exchange":"SHG","isin":"CNE1000030G4","titleCount":0,"contentCount":1,"primary":false},{"name":"Overstock.com Inc","symbol":"OVER","exchange":"FRA","isin":"US6903701018","titleCount":0,"contentCount":1,"primary":false},{"name":"Overstock.com Inc","symbol":"OVER","exchange":"MUN","isin":"US6903701018","titleCount":0,"contentCount":1,"primary":false},{"name":"Overstock.com Inc","symbol":"OSTK","exchange":"NAS","isin":"US6903701018","titleCount":0,"contentCount":1,"primary":false},{"name":"Overstock.com Inc","symbol":"OVER","exchange":"STU","isin":"US6903701018","titleCount":0,"contentCount":1,"primary":false},{"name":"Overstock.com Inc","symbol":"OSTBP","exchange":"PINX","isin":"US6903703097","titleCount":0,"contentCount":1,"primary":false},{"name":"Overstock.com Inc","symbol":"OSTKP","exchange":"PINX","isin":"US6903704087","titleCount":0,"contentCount":1,"primary":false}],"author":{"name":"Trent Williams","publishingPlatform":{}},"licenses":[{"name":"Publicly Available"}],"source":{"name":"Community Financial News","homeUrl":"https://www.com-unik.info","category":"Trade","editorialRank":"5","location":{"country":"United States","countryCode":"US","region":"Americas","subregion":"Northern America"},"feed":{"id":"637628019","name":"Community Financial News","mediaType":"News","tags":[],"language":"Unassigned","dataFormat":"text","rank":{"inboundLinkCount":"0"},"inWhiteList":"true","autoTopics":[],"editorialTopics":["Professional","Financials"],"genre":"General"}},"es_id":86994457}